Sonnet Biotherapeutics Holdings Inc (SONN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sonnet Biotherapeutics Holdings Inc (SONN) has a cash flow conversion efficiency ratio of 0.577x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.76 Million) by net assets ($-3.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sonnet Biotherapeutics Holdings Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Sonnet Biotherapeutics Holdings Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Sonnet Biotherapeutics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sonnet Biotherapeutics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sonnet Biotherapeutics Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Together Startup Network Ltd
TA:TGTR
|
-0.149x |
|
Magontec Ltd
AU:MGL
|
0.008x |
|
Labrador Gold Corp
V:LAB
|
-0.002x |
|
Battery Age Minerals Ltd
AU:BM8
|
-0.053x |
|
Ease2pay NV
AS:EAS2P
|
-0.009x |
|
Watta Holding Bhd
KLSE:7226
|
-0.034x |
|
Raketech Group Holding
ST:RAKE
|
0.043x |
|
ERG S.A.
WAR:ERG
|
0.048x |
Annual Cash Flow Conversion Efficiency for Sonnet Biotherapeutics Holdings Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Sonnet Biotherapeutics Holdings Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Sonnet Biotherapeutics Holdings Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $10.79 Million | $-12.83 Million | -1.189x | -106.71% |
| 2024-09-30 | $-485.74K | $-8.61 Million | 17.721x | -81.24% |
| 2023-09-30 | $-225.98K | $-21.34 Million | 94.441x | +765.96% |
| 2022-09-30 | $-2.54 Million | $-27.69 Million | 10.906x | +1176.46% |
| 2021-09-30 | $22.26 Million | $-22.55 Million | -1.013x | +80.41% |
| 2020-09-30 | $3.02 Million | $-15.61 Million | -5.171x | -761.04% |
| 2019-09-30 | $-2.85 Million | $-2.23 Million | 0.782x | +1340.48% |
| 2017-09-30 | $11.49 Million | $-724.43K | -0.063x | -72.91% |
| 2016-09-30 | $13.96 Million | $-509.16K | -0.036x | +85.21% |
| 2015-12-31 | $21.76 Million | $-5.36 Million | -0.247x | +31.18% |
| 2015-09-30 | $14.97 Million | $-5.36 Million | -0.358x | -48.88% |
| 2013-09-30 | $11.24 Million | $-2.70 Million | -0.241x | +62.19% |
| 2012-09-30 | $1.64 Million | $-1.04 Million | -0.636x | -6798.55% |
| 2011-09-30 | $82.42 Million | $-760.31K | -0.009x | +98.96% |
| 2009-09-30 | $718.02K | $-636.48K | -0.886x | -- |
About Sonnet Biotherapeutics Holdings Inc
As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that bin… Read more